NEJM:Tabrecta treats METex14-jumping non-small cell lung cancer with positive results from key studies.

Data from a key GEOMETRY mono-1 II study published recently in the New England Journal of Medicine (NEJM) show positive results in the treatment of MET exon 14 (METex14) with Tabrecta™
met is a Tyrosine kinase encoded by the MET gene, which usually plays an important role in cell signaling, proliferation and survival.
many cancers are associated with abnormal signaling of the MET subject pathway, which is caused by a variety of mechanisms, including point mutations, insertions/missing exon 14 jumps.
Jeff Legos, head of oncology development at Novart, said: "The data published today not only confirm our previous positive results in the use of Tabrecta in non-small cell lung cancer, but also highlight the value of early and extensive molecular testing of patient tumors to guide treatment options.
we know that patients with this aggressive lung cancer have poor prognosis and tend to be older.
we are committed to working with global health authorities to bring Tabrecta to patients as soon as possible."
independent radiology committee (BIRC) conducted an ORR analysis of Tabrecta's treatment of MET exon 14 jump patients (n s 97) and the results showed that the ORR rate of first-time patients (n s 28) was 68% (95% CI 48-84) and that the ORR rate of previously treated patients (n s 69) was 41% (95% CI 29-53).
.